Literature DB >> 23485110

Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth.

Yan-Xia Zhang1, Zhen Yue, Ping-Yu Wang, You-Jie Li, Jia-Xuan Xin, Min Pang, Qing-Yin Zheng, Shu-Yang Xie.   

Abstract

miR-21 can act as an oncogene. MSH2 has been reported that it involved in the DNA mismatch repair (MMR) system and overexpression of MSH2 can induce cell apoptosis. We predicted that MSH2-3'-untranslated region (3'-UTR) was targeted by miR-21 using microRNA analysis softwares. To further explore the roles of miR-21 and MSH2 in A549 cells, we constructed pcDNA-GFP-msh-UTR vector (including MSH2-3'-UTR) to transfect A549 cells with miR-21, GFP positive cells were estimated under a fluorescence microscopy and by flow cytometry. We found miR-21 could obviously downregulate the expression of MSH2, which was further proved by western blotting. Moreover, we treated A549 cells with cisplatin and found that cisplatin could inhibit A549 cell growth in vitro and in vivo. We also found that cisplatin could downregulate miR-21 expression, while increase MSH2 expression in A549 cells. Our results demonstrated that cisplatin could upregulate the expression of MSH2 through downregulating miR-21 to inhibit A549 cell proliferation, which provides new gene targets for drug design or cancer therary.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23485110      PMCID: PMC3646586          DOI: 10.1016/j.biopha.2012.11.008

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  38 in total

Review 1.  The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis.

Authors:  R Fishel
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.

Authors:  Victor Ambros
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 4.  Genetic susceptibility to lung cancer: the role of DNA damage and repair.

Authors:  Margaret R Spitz; Qingyi Wei; Qiong Dong; Christopher I Amos; Xifeng Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-08       Impact factor: 4.254

Review 5.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

6.  hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.

Authors:  S Acharya; T Wilson; S Gradia; M F Kane; S Guerrette; G T Marsischky; R Kolodner; R Fishel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

7.  Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.

Authors:  G V Dedoussis; A Mouzaki; M Theodoropoulou; P Menounos; M C Kyrtsonis; A Karameris; A Maniatis
Journal:  Exp Cell Res       Date:  1999-06-15       Impact factor: 3.905

8.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

9.  Purified human MSH2 protein binds to DNA containing mismatched nucleotides.

Authors:  R Fishel; A Ewel; M K Lescoe
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

10.  An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.

Authors:  Diana P Lin; Yuxun Wang; Stefan J Scherer; Alan B Clark; Kan Yang; Elena Avdievich; Bo Jin; Uwe Werling; Tchaiko Parris; Naoto Kurihara; Asad Umar; Raju Kucherlapati; Martin Lipkin; Thomas A Kunkel; Winfried Edelmann
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

View more
  7 in total

1.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 2.  DNA damage response in cisplatin-induced nephrotoxicity.

Authors:  Shiyao Zhu; Navjotsingh Pabla; Chengyuan Tang; Liyu He; Zheng Dong
Journal:  Arch Toxicol       Date:  2015-11-13       Impact factor: 5.153

Review 3.  MicroRNAs in the DNA Damage/Repair Network and Cancer.

Authors:  Alessandra Tessitore; Germana Cicciarelli; Filippo Del Vecchio; Agata Gaggiano; Daniela Verzella; Mariafausta Fischietti; Davide Vecchiotti; Daria Capece; Francesca Zazzeroni; Edoardo Alesse
Journal:  Int J Genomics       Date:  2014-01-30       Impact factor: 2.326

4.  miR-21 promotes human nucleus pulposus cell proliferation through PTEN/AKT signaling.

Authors:  Hongzhe Liu; Xiangwang Huang; Xiangyang Liu; Sheng Xiao; Yi Zhang; Tiecheng Xiang; Xiongjie Shen; Guoping Wang; Bin Sheng
Journal:  Int J Mol Sci       Date:  2014-03-05       Impact factor: 5.923

5.  Cisplatin decreases cyclin D2 expression via upregulating miR‑93 to inhibit lung adenocarcinoma cell growth.

Authors:  Ning Xie; Yuan-Rong Liu; Yan-Mei Li; Ya-Nan Yang; Li Pan; Yu-Bo Wei; Ping-Yu Wang; You-Jie Li; Shu-Yang Xie
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

Review 6.  Role of microRNAs in intervertebral disc degeneration (Review).

Authors:  Fengguang Yang; Jizu Wang; Zhixin Chen; Yuping Yang; Wenhui Zhang; Shifang Guo; Qingshan Yang
Journal:  Exp Ther Med       Date:  2021-06-10       Impact factor: 2.447

7.  Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.

Authors:  Ewa Maj; Beata Filip-Psurska; Magdalena Milczarek; Mateusz Psurski; Andrzej Kutner; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2017-12-15       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.